Soru

Zorluk: OrtaEnd-of-Life and Palliative Care

A 68-year-old man with advanced idiopathic pulmonary fibrosis is admitted to an inpatient hospice unit. Over the next several days, his respiratory status declines, and he develops progressive, severe dyspnea that causes him significant distress. The medical team plans a stepwise approach to symptom management. Arrange the following interventions in the most appropriate sequential order for managing this patient's progressive terminal dyspnea, from the initial first-line approach to the final intervention of last resort for truly refractory symptoms.

  1. 1Implement non-pharmacologic measures, such as a bedside fan directed at the face, repositioning, and relaxation techniques.
  2. 2Initiate and carefully titrate systemic opioids (e.g., low-dose oral or intravenous morphine) to relieve breathlessness.
  3. 3Add a systemic benzodiazepine (e.g., lorazepam) to address significant anxiety exacerbating the sensation of dyspnea.
  4. 4Initiate palliative sedation to unconsciousness (e.g., continuous midazolam infusion) for refractory symptoms.

Cevap

The correct sequence is: Non-pharmacologic measures, followed by systemic opioids, then addition of benzodiazepines for anxiety, and finally palliative sedation for refractory symptoms.
The correct sequence follows the standard palliative care protocol for terminal dyspnea. It begins with low-risk, high-yield non-pharmacologic interventions (like a fan). When these are insufficient, systemic opioids are the evidence-based first-line pharmacologic treatment. If dyspnea causes severe panic or anxiety that persists despite opioids, anxiolytics like benzodiazepines are added. Finally, if the symptom becomes truly refractory and causes intolerable suffering, palliative sedation is employed to relieve distress.

Adım Adım Çözüm

1
Identify the primary symptom and clinical context.
The patient is experiencing progressive terminal dyspnea in a hospice setting.
Establishing the goals of care (comfort) dictates the treatment pathway.
2
Determine the first-line, lowest-risk intervention.
Non-pharmacologic measures (e.g., a fan to the face) are implemented.
These interventions carry no physiological risk and stimulate trigeminal nerve receptors to reduce the sensation of dyspnea.
3
Select the primary pharmacologic agent for dyspnea.
Systemic opioids are initiated and titrated.
Opioids are the gold standard for relieving dyspnea in terminal illness by decreasing respiratory drive and altering the perception of breathlessness.
4
Address secondary compounding factors if initial pharmacology is insufficient.
Benzodiazepines are added to manage anxiety.
Anxiety often accompanies and exacerbates dyspnea; benzodiazepines help break this cycle when opioids alone are inadequate.
5
Determine the course of action for truly refractory, intolerable symptoms.
Palliative sedation is initiated.
When all other measures fail to provide comfort at the end of life, sedation to unconsciousness is ethically and clinically appropriate.

Anahtar Kavram

The stepwise management of terminal dyspnea prioritizes non-pharmacologic measures, followed by opioids as the primary pharmacologic treatment, adjuvants like benzodiazepines for anxiety, and palliative sedation only as a last resort.
Bu soruyu puanla